Viewpoint
Long-Term Durability of Transcatheter Valves: The Importance of Accurate Data

https://doi.org/10.1016/j.jcin.2019.10.003Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Echocardiographic definitions of structural valve deterioration must include a change in leaflet morphology accompanied by a deterioration in hemodynamic function.

  • An absolute mean gradient equal or >20 mm Hg can occur as a result of patient-prosthesis mismatch and cannot, alone, be used to define structural valve deterioration.

  • Studies of replacement valve durability should use core laboratories and report the percentage of patients having serial echocardiography.

Abstract

As transcatheter valves are offered to progressively lower-risk patients, it is increasingly important to have accurate data about durability. Structural valve deterioration (SVD) implies an adverse change in the morphology of the leaflets and function of the valve compared with the state at implantation. However, a recent European statement allows SVD to be defined solely by a threshold mean gradient ≥20 mm Hg. Absolute mean gradients above this threshold may be observed immediately after implantation and represent patient–prosthesis mismatch and not SVD. This paper describes a definition of SVD more in keeping with routine clinical practice, incorporating a change in leaflet morphology and an increase in the grade of transvalvar regurgitation or an increase in gradient from the post-implantation study.

Key Words

echocardiography
structural valve deterioration
surgical valve replacement
transcatheter valve replacement

Abbreviations and Acronyms

SAVR
surgical aortic valve replacement
SVD
structural valve deterioration
TAVR
transcatheter aortic valve replacement

Cited by (0)

Prof. Chambers has been a consultant for Cryolife and Medtronic. Dr. Borer has been a consultant for Boehringer Ingelheim and Servier; and has served on Data Safety Monitoring Boards for GlaxoSmithKline, Alnylam, Novartis, Pfizer, and General Electric. Dr. Yoganathan has received research funding from Boston Scientific, Abbott, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.